Sunquest posts loss despite strong growthTucson, AZ-based Sunquest Information Systems reported a 25% increase in revenue for its third quarter. Despite healthy revenue growth, however, earnings before write-offs were below analysts'
Tucson, AZ-based Sunquest Information Systems reported a 25% increase in revenue for its third quarter. Despite healthy revenue growth, however, earnings before write-offs were below analysts' expectations.
For the third quarter (end-September), Sunquest had revenues of $24.3 million, compared with $19.3 million for the same period in 1996. The company reported a net loss after write-offs of $268,000, compared with a net income of $1.7 million for the third quarter in 1996.
Sunquest had two sizable write-offs in the quarter: $1.3 million for in-process technology acquired in connection with the purchase of the PreciseCare Medication Management System from Medintell Systems and $1.5 million for previously capitalized software development costs relating to Sunquest's IntelliCarer suite of products.
The primary reason the company failed to meet analysts' expectations for earnings before write-offs was delays in customer installation schedules and the resultant delays in revenue recognition, said Dr. Sidney Goldblatt, president and CEO. The company is taking steps to mitigate these delays by increasing staff in certain areas such as interfacing, customer training, and targeted consulting.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.